Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nevan Charles Elam
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
- Beta
- 0.61
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 10.41
Financials
Revenue
$0.00-100.0%Net Income
$-20.49MEBITDA
$-21.56MFree Cash Flow
$-13.15MEPS (diluted)
$-0.20Shares Outstanding (diluted)
104.49M+14658.0%Operating Expenses
$21.56MCash & Debt
$107.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-77.59M | $-0.75 |
| 2025 | $0.00 | $-74.41M | $-0.98 |
| 2024 | $0.00 | $-68.46M | $-1.33 |
| 2023 | $0.00 | $-51.79M | $-1.01 |
| 2022 | $0.00 | $-41.06M | $-2.26 |
| 2021 | $0.00 | $-20.90M | $-2.72 |
| 2020 | $0.00 | $-20.33M | $-3.54 |
| 2019 | $0.00 | $-30.42M | $-17.11 |
| 2018 | $0.00 | $-29.86M | $-26.83 |
| 2017 | $0.00 | $-20.28M | $-24.55 |
| 2016 | $0.00 | $-14.94M | $-30.14 |
| 2015 | $0.00 | $-11.36M | $-27.12 |
| 2014 | $0.00 | $-9.73M | $-51.84 |
| 2013 | $0.00 | $-6.73M | $-54.21 |
Valuation
RZLThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·19d ago·Neutral
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities
View source ↗ - Newsglobenewswire.com·30d ago·Negative
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026.
View source ↗ - Newsglobenewswire.com·45d ago·Negative
…HI and the Company remains on track to report topline results before the end of 2026 REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today provided an update on the status of the ongoing U.S. Food and Drug Administration (“FDA” or “Agency”) review of data from the Company's Phase 3 sunRIZE study of …
View source ↗ - Newsglobenewswire.com·52d ago·Negative
Rezolute to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
View source ↗
Earnings
Thu, Nov 5(in 11 days)
Consensus estimate $-0.18 per share
Typical surprise -13.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Sep 24$-0.20 vs $-0.15miss
- Tue, May 12$-0.16 vs $-0.14miss
- Thu, Feb 12$-0.22 vs $-0.16miss
- Thu, Nov 6$-0.18 vs $-0.27beat
- Wed, Sep 17$-0.26 vs $-0.23miss
- Tue, May 13$-0.27 vs $-0.22miss
Estimates and results for RZLT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RZLT officers and directors.
- Bought
- $9.8m
- Sold
- —
33 trades
0 trades
- Evans Daronbought
- Hogenhuis Wladimirbought
- Roberts Brian Kennethbought
- Evans Daronbought
- Evans Daronbought
- Evans Daronbought
- Elam Nevan Cbought
- Karnawat Sunil Ratilalbought
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RZLT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.